Erythin^®

Erythromycin is an azalide, derived from the macrolide class of antibiotics.

No Data

Erythin® is indicated for prophylaxis and management of the following clinical conditions.
-Upper respiratory tract infections: tonsillitis, pharyngitis, laryngitis, sinusitis, peritonsillar secondary infections in cold and influenza.
-Lower respiratory tract infections: tracheatis, bronchitis, bronchopneumonia, pertussis, legionnaries disease.
-Ear infection: Otitis media, otitis externa, rnastoiditis.
-Skin and soft tissue infections.
-Oral infections: gingivitis, vincents angina.
-Gastro-intestinal and biliary infection.

Adult and child over I years: 250 to 500mg tablet every 6 hourly or 500mg to 19 every 12 hourly. ln case ol severe infection 49 daily. ln case of early syphilis, 500mg tablet 4 times daily for 14 days. Uncomplicated genital chlamydia, nongonococcal urethritis, 500mg tablet twice daily for 14 days.

Child: The usual dose is 30 to S0mg/kg/day in divided doses. Doses should be doubled for severe infections
Children 2 to 8 years: 2S0mg every 6 hourly.
Children up to 2 years: 125mg every 6 hourly.

No Data

No Data

No Data

Erythromycin is one of the safer antibiotics, gastrointestinal disturbances and allergy being the commonest adverse reactions.

• diarrhea
• vomiting
• stomach cramps
• mild skin rash

Erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. it is also contraindicated in patients taking terfenadine, astemizole, or cisapride.
Precautions: Erythromycin should be given with care in patients with impaired hepatic function.

Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
Concomitant administration of Erythromycin and Digoxin have been reported to result in elevated Digoxin serum levels.
There have been reports of increased anticoagulant effects when Erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation etfects due to interactions of Erythromycin with various oral anticoagulants may be-more pronounced in the elderly.
There have been reports of interactions of Erythromycin with
Carbamazepine, Cyclosporine, Tacrolimus, Hexobarbital, Phenytoin, Alfentanil, Cisapride, Disopyramide, Lovastatin, Bromocriptine, Valproate, Terfenadine, and Astemizole. Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving Enythromycin. Erythromycin has been reported to significantly alter the metabolism ofnonsedating Antihistamines, Terfenadine and Astemizole when taken concomitantly.

Erythromycin should be discontinued in case of overdosage. Overdosage should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures.
Erythromycin is not removed by peritoneal dialysis or hemodialysis.

No Data

Store in a cool and dry place. Protect from tight.